PECARN Fever Nuances

Well-appearing febrile infants 8 to 60 days old can often be managed with less invasive testing and fewer hospitalizations under the PECARN-informed AAP guideline. Risk stratification now hinges on age bands, urinalysis, and inflammatory markers, while HSV screening remains a separate early safety check.

PECARN Approach to Young Infant Fever

• Eligible infant definition: The pathway applies to well-appearing term infants 8 to 60 days old with a documented rectal temperature of at least 38.0 C at home or in the ED, while preterm, bronchiolitic, medically fragile, and first-week-of-life infants sit outside the rule.
• Inflammatory marker triad: Procalcitonin, CRP, and absolute neutrophil count now drive low-risk classification, allowing many infants to avoid lumbar puncture or admission when the marker pattern is reassuring. We walk through the bedside interpretation in the episode.
• Youngest infant default: Infants 8 to 21 days old still get a full sepsis evaluation with LP, parenteral antibiotics, and admission; this remains the highest-risk age band despite the newer pathway.
• Intermediate age nuance: For infants 22 to 28 days old, inflammatory markers and CSF findings determine how far you can safely de-escalate, and even with a normal workup the residual bacteremia risk is still about 1 to 2 percent.
• Older infant de-escalation: In infants 29 to 60 days old, a normal inflammatory marker set plus urinalysis can support discharge without LP, and a positive UA can often be managed as outpatient UTI with oral therapy.

HSV Risk and Antibiotic Updates

• Vertical HSV red flags: Maternal genital HSV history or peripartum fever, plus infant vesicles, seizure, hypothermia, mucosal ulcers, cytopenias, or transaminitis should trigger HSV PCR testing and empiric acyclovir.
• Ceftazidime replacing cefotaxime: Cefotaxime is no longer manufactured in the US, so ceftazidime becomes the key third-generation cephalosporin in these regimens; the swap is logistical rather than resistance-driven.
• Ampicillin coverage rationale: Ampicillin stays in the youngest infant regimens to preserve Enterococcus and Listeria coverage, a reminder that neonatal pathogen patterns still differ from older children.
• ESBL community adjustment: Gentamicin can replace ceftazidime when local ESBL-producing E. coli circulation is a concern, an antibiotic-selection nuance that matters more than memorizing a one-size-fits-all regimen.
• Viral testing caveat: A positive viral panel does not meaningfully lower concern in the youngest febrile infants, while bronchiolitis is excluded from this algorithm altogether. We get into the exceptions in the chapter.

References: 

 

1. Pantell RH, Roberts KB, Adams WG, et al. Evaluation and Management of Well-Appearing Febrile Infants 8 to 60 Days Old [published correction appears in Pediatrics. 2021 Nov;148(5):]. Pediatrics. 2021;148(2):e2021052228. doi:10.1542/peds.2021-052228 PMID: 34281996